Fluid attenuated inversion recovery imaging based intravenous recombinant tissue plasminogen activator (rt-PA) therapy

Fluid attenuated inversion recovery imaging based intravenous recombinant tissue plasminogen activator (rt-PA) therapy - Fluid attenuated inversion recovery imaging based intravenous recombinant tissue plasminogen activator (rt-PA) therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001808

Enrollment

Registered

2009-07-01

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

intravenous recombinant tissue plasminogen activator (rt-PA) therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with unknown onset time 2) Arterial lesion of anterior circulation on magnetic resonance angiography 3) The findings of fluid attenuated inversion recovery imaging is negative

Exclusion criteria

Exclusion criteria: 1) Patients with suspected onset time is over 24 hours 2) Diffusion weighted imaging evidence of significant early ischemic change 3) Other criteria are same as Japan Alteplase Clinical Trial (J-ACT) (stroke 2006;37:1810)

Design outcomes

Primary

Measure	Time frame
1)Clinical improvement 2)hemorrhagic complication	—

Countries

Japan

Contacts

Public ContactJunya Aoki

Kawasaki Medical School Department of Stroke Medicine

aojyun@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026